查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018786

食品過敏診斷和治療市場：按產品類型、過敏原類型、最終用戶和分銷管道分類－2026-2032年全球市場預測

Food Allergy Diagnostics & Therapeutics Market by Product Type, Allergen Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，食品過敏診斷和治療市場價值將達到 71.4 億美元，到 2026 年將成長至 79.3 億美元，到 2032 年將達到 145.7 億美元，複合年成長率為 10.72%。

主要市場統計數據
基準年 2025 71.4億美元
預計年份：2026年 79.3億美元
預測年份 2032 145.7億美元
複合年成長率 (%) 10.72%

介紹不斷發展的食物過敏診斷和治療市場，重點關注患者療效、創新和政策因素。

在臨床創新、照護模式轉變以及保險公司和監管機構日益重視的推動下，食物過敏的診斷和治療領域正經歷結構性變革。能夠更精準地識別致敏模式的診斷技術與旨在持續調節免疫功能的治療方法相融合，使得臨床醫生、實驗室技術人員和行業合作夥伴之間的合作比以往任何時候都更加緊密。

識別臨床實踐、技術應用、支付方參與和患者行為的變革性變化，這些變化將重塑診斷和治療路徑。

近年來，過敏症的診療和商業化模式正經歷著許多轉折點，這些轉折點正在全面重塑過敏症的診療方式。檢測法和分子成分診斷等技術的進步，使臨床醫生能夠獲得詳細的過敏原信息，從而指南精準治療；同時，數位化工具和遠距醫療也拓展了篩檢和長期監測的範圍。此外，治療方法也日趨多樣化。儘管傳統的抗組織胺和緊急治療仍是治療的基礎，但免疫療法和生物製藥的出現正在加速向長期疾病管理模式的轉變。

評估美國自 2025 年起徵收關稅對供應鏈、試劑採購、臨床試驗、定價策略和國際合作的影響。

2025年實施的政策措施，例如關稅上調和結構調整，對參與過敏診斷和治療的製造商、經銷商和臨床實驗室帶來了重大影響。在跨境貿易中，生物製藥所需的專用試劑、檢測組件和原料等供應鏈受到的影響尤其顯著。隨著運輸路線日益複雜，採購團隊正在重新審視其籌資策略，以降低關稅波動帶來的風險，並確保供應的連續性。

深入分析產品類型、過敏原類別、最終用戶和分銷管道如何驅動臨床應用和商業策略。

基於產品類型、過敏原特異性、終端用戶環境和通路的細分分析可提供實用見解。診斷測試包括家庭過敏測試、成分分解測試、皮膚點刺試驗和特異性IgE測試，每種測試都具有獨特的臨床效用和實施模式，影響檢查室工作流程和臨床決策。治療產品包括抗組織胺和急救藥物，這些藥物仍然必不可少。同時，經皮、口服或皮下免疫療法以及單株抗體構成了一種長期管理模式，需要個別化的實證策略。

深入分析美洲、歐洲、中東和非洲以及亞太地區在全球展現的獨特監管、贖回和市場動態。

區域趨勢對診斷和治療創新技術的研發、推廣和報銷方式有顯著影響。在美洲，我們持續看到活躍的臨床研究和多元化的經營模式強調在門診和住院環境中快速推廣新的診斷方法和專科療法。相較之下，歐洲、中東和非洲的監管和報銷體係錯綜複雜，各國在努力實現協調統一的同時，也存在差異，因此需要有針對性的證據組合和區域性定價策略。

深入了解診斷和治療領域主要企業的競爭考察、策略聯盟、研發投資和優先事項。

診斷和治療領域主要企業之間的競爭格局呈現出差異化的產品組合、策略聯盟以及針對性研發投入的特徵。一些公司專注於多重診斷平台和分子水平檢測，以實現更精準的患者分層；而另一些公司則優先開發旨在改變疾病進程的免疫療法和生物製藥。在需要持續證據和協作式研發路徑的整合醫療模式下，診斷創新者和治療藥物開發商之間的合作正變得日益普遍。

建議領導者加快患者獲得過敏治療的途徑，最佳化供應鏈，與支付方合作，並優先考慮具有影響力的創新。

該領域的領導者應採取務實且以患者為中心的行動，將創新轉化為可近的醫療保健。首先，在研發早期階段，應使證據產生與支付方和監管機構的期望保持一致，確保臨床檢驗、衛生經濟學和真實世界證據的收集能夠為有關報銷和處方藥清單的討論提供支持。其次，應最佳化供應商、評估區域生產方案以及維持儲備庫存，以降低貿易政策變化的風險。

透明的調查方法，概述了資料來源、分析技術、檢驗程序和倫理考量，以產生可靠的產業洞察。

本研究基於一套系統性的調查方法，該方法結合了與關鍵相關人員的對話、對二手資訊的嚴格整合以及反覆檢驗。關鍵資訊輸入包括與臨床醫生、檢查室管理人員、公司高管、支付方以及患者權益倡導團體代表的訪談和諮詢，以確保研究結果反映現實世界的決策因素。二手資訊的整合利用了同行評審文獻、監管指南、臨床試驗註冊資訊以及公開的技術信息，從而為主要研究結果提供背景資訊。

區域結論總結了對相關人員的影響，並重點介紹了能夠改善創新路徑、業務永續營運和患者療效的合作模式。

整體情況，所考察的證據表明，過敏診斷和治療的持續進展取決於涵蓋技術開發、證據生成、供應鏈韌性和相關人員參與等方面的協作努力。診斷準確性的提高有助於更好地對患者進行分層，而多樣化的治療方法則為從症狀控制轉向疾病改善提供了契機。同時，考慮到監管和報銷方面的實際情況，有針對性的證據以及與保險公司的建設性溝通對於實現常規臨床應用至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：食物過敏診斷與治療市場：依產品類型分類

  • 診斷測試
    • 家用過敏測試
    • 成分分解診斷
    • 皮膚點刺試驗
    • 特異性IgE檢測
  • 治療產品
    • 抗組織胺藥
    • 緊急治療
    • 免疫療法
      • 經皮免疫療法
      • 口服免疫療法
      • 皮下免疫療法
    • 單株抗體

第9章 依過敏原類型分類的食物過敏診斷與治療市場

  • 雞蛋過敏
  • 魚類過敏
  • 牛奶過敏
  • 花生過敏
  • 芝麻過敏
  • 貝類過敏
  • 大豆過敏
  • 堅果過敏
  • 小麥過敏

第10章 食品過敏診斷與治療市場：依最終使用者分類

  • 醫院檢查室
  • 即時偵測（PoC）環境
  • 參考實驗室
  • 研究機構

第11章 食品過敏診斷與治療市場：依通路分類

  • 診所和診斷中心
  • 醫院
  • 線上
  • 藥局

第12章 食品過敏診斷與治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 食物過敏診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 食品過敏診斷與治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國食物過敏診斷與治療市場

第16章：中國食物過敏診斷與治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ALK-Abello A/S
  • Allergy Therapeutics plc
  • bioMerieux SA
  • DBV Technologies SA
  • Eurofins Scientific SE
  • HAL Allergy Group
  • HOB Biotech Group Corp. Ltd.
  • HYCOR Biomedical
  • Immunomic Therapeutics Inc.
  • Lincoln Diagnostics Inc.
  • Medeca Pharma AB
  • NEOGEN Corporation
  • Nestle Health Science SA
  • Omega Diagnostics Group PLC
  • Pfizer Inc.
  • Prota Therapeutics Pty Ltd
  • Quest Diagnostics Incorporated
  • R-Biopharm AG
  • Sanofi SA
  • Siemens Healthineers AG
  • Stallergenes Greer International SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E8118

The Food Allergy Diagnostics & Therapeutics Market was valued at USD 7.14 billion in 2025 and is projected to grow to USD 7.93 billion in 2026, with a CAGR of 10.72%, reaching USD 14.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.14 billion
Estimated Year [2026] USD 7.93 billion
Forecast Year [2032] USD 14.57 billion
CAGR (%) 10.72%

A concise introduction to the evolving food allergy diagnostics and therapeutics landscape emphasizing patient outcomes, innovation, and policy drivers

The food allergy diagnostics and therapeutics sector is experiencing a period of structured advancement driven by clinical innovation, changing care models, and intensified attention from payers and regulators. Diagnostic technologies that enable more precise identification of sensitization patterns are converging with therapeutic approaches that seek durable immune modulation, producing an environment in which clinicians, laboratorians, and industry partners must coordinate more closely than ever before.

As the clinical community adopts component-resolved diagnostics and at-home screening options, therapeutic pipelines are simultaneously shifting from symptom control toward disease-modifying approaches. This dual movement compels stakeholders to reassess clinical pathways, evidence generation strategies, and commercial models. Moving forward, successful initiatives will integrate rigorous clinical validation, payer-engaged health economic rationale, and clear patient-centered value propositions to translate laboratory advances into improved outcomes and more efficient care delivery.

Identifying transformative shifts in clinical practice, technology adoption, payer engagement, and patient behavior reshaping diagnostic and therapeutic routes

Recent years have seen multiple inflection points that collectively redefine how allergy care is delivered and commercialized. Technological advances such as multiplexed assays and molecular component diagnostics are providing clinicians with granular profiles that inform precision treatment, while digital tools and remote testing expand the reach of screening and longitudinal monitoring. Concurrently, therapeutic approaches have diversified: traditional antihistamines and emergency interventions remain foundational, but immunotherapy modalities and biologic agents are prompting shifts toward long-term disease management.

Alongside technology and clinical practice changes, payer frameworks and regulatory expectations are evolving, pressing stakeholders to demonstrate real-world benefits and cost-effectiveness. Patient expectations are also a powerful driver; convenience, safety, and measurable improvements in quality of life are guiding uptake. Taken together, these shifts create a landscape in which integrated strategies across diagnostics, therapeutics, and care delivery models are essential for sustainable adoption and meaningful improvements in patient outcomes.

Assessing impact of US tariffs from 2025 on supply chains, reagent sourcing, clinical trials, pricing strategies and international collaboration

Policy actions implemented in 2025 that increase or alter tariff structures have introduced material considerations for manufacturers, distributors, and clinical laboratories engaged in allergy diagnostics and therapeutics. The effects are most visible along supply chains where specialized reagents, assay components and biologic drug ingredients cross borders. As shipping paths become more complex, procurement teams are reallocating sourcing strategies to reduce exposure to tariff volatility and to preserve continuity of supply.

Clinical trial sponsors and research institutions are likewise adapting protocols and budgets to accommodate potential cost escalations associated with imported materials or outsourced testing services. These adjustments frequently involve earlier engagement with manufacturing partners, consideration of regional manufacturing alternatives, and a heightened focus on inventory planning. Commercial teams are reallocating pricing and contracting levers when necessary, while payers are being engaged proactively to discuss the implications for reimbursement of higher-cost products or new technologies. In the near term, organizations that prioritize supply chain diversification, strengthen supplier agreements, and accelerate localization of key inputs will be better positioned to mitigate tariff-induced disruptions and sustain development and delivery timelines.

Key segmentation insights on how product types, allergen categories, end users and distribution channels drive clinical uptake and commercial strategy

Segmentation analysis reveals practical insights when examined through the lens of product type, allergen specificity, end-user setting, and distribution pathway. Diagnostic tests encompass at-home allergy tests, component resolved diagnostics, skin prick tests, and specific IgE tests, each presenting distinct clinical utility and adoption profiles that influence laboratory workflows and point-of-care decision making. Therapeutic products include antihistamines and emergency treatments that remain essential, while immunotherapy-delivered via epicutaneous, oral, or subcutaneous routes-together with monoclonal antibodies shape the longer-term management paradigm and demand tailored evidence strategies.

Allergen type introduces further nuance: egg, milk, peanut, tree nut, shellfish, sesame, soy, fish, and wheat allergies present different diagnostic challenges, patient education needs, and therapy tolerability considerations. End users such as hospital laboratories, point-of-care settings, reference laboratories, and research institutes exhibit varying procurement behaviors, technical capabilities and preferences for companion diagnostics. Finally, distribution channels including clinics and diagnostic centers, hospitals, online platforms and pharmacies determine patient access pathways and commercial models. Integrating these segmentation dimensions supports strategic decisions about product positioning, evidence generation, and go-to-market approaches that align with clinical workflows and patient journeys.

Regional insights on how the Americas, Europe, Middle East & Africa and Asia-Pacific present distinct regulatory, reimbursement and market dynamics globally

Regional dynamics materially influence how diagnostic and therapeutic innovations are developed, adopted, and reimbursed. The Americas continue to demonstrate robust clinical research activity and a diverse set of commercial models that emphasize rapid integration of new diagnostics and specialty therapeutics in both ambulatory and hospital settings. In contrast, Europe, Middle East & Africa offer a complex regulatory and reimbursement mosaic where harmonization efforts coexist with country-level variability, requiring targeted evidence packages and localized pricing strategies.

Asia-Pacific presents a heterogeneous mix of high-capacity manufacturing hubs and rapidly expanding patient access initiatives; engagement in this region often centers on regulatory alignment, technology transfer, and scalable distribution solutions. Across all regions, cross-border collaboration in research, harmonized regulatory interactions, and investment in local clinical capacity are recurring themes that enable broader adoption and more resilient supply chains. Understanding these regional differences is essential for calibrating commercialization efforts and prioritizing investment in regulatory and payer engagement.

Key companies insights on competitive positioning, strategic partnerships, R&D investment and priorities among diagnostic and therapeutic leaders

Competitive dynamics among leading companies in diagnostics and therapeutics are characterized by differentiated portfolios, strategic partnerships, and targeted investment in research and development. Some firms are concentrating on multiplexed diagnostic platforms and molecular-level assays to enable more precise patient stratification, while others prioritize development of immunotherapies and biologics designed to alter disease trajectory. Collaboration between diagnostic innovators and therapeutic developers is increasingly common as integrated care models require aligned evidence and co-development pathways.

Investment strategies reflect a balance between near-term commercial priorities and long-term pipeline development. Strategic partnerships-including distribution agreements, R&D collaborations and licensing arrangements-are accelerating access to complementary capabilities. Operational priorities often focus on strengthening manufacturing resilience, securing reagent supply, and implementing scalable quality systems to meet diverse regulatory requirements. Stakeholders that clearly communicate clinical value, align evidence generation with payer needs, and establish interoperable clinical workflows gain advantage in a market where clinical credibility and logistical reliability matter most.

Recommendations for leaders to accelerate patient access, optimize supply chains, align with payers, and prioritize impactful innovation for allergy care

Leaders in the field should adopt a pragmatic and patient-centered set of actions to translate innovation into accessible care. First, align evidence generation with payer and regulatory expectations early in development so that clinical validation, health economics and real-world evidence collection support reimbursement and formulary discussions. Second, optimize supply chain strategies by diversifying suppliers for critical reagents, evaluating regional manufacturing options, and establishing contingency inventory to reduce exposure to trade-policy fluctuations.

Third, prioritize interoperability and clinician engagement by designing diagnostics and therapy introduction programs that fit seamlessly into existing clinical workflows and deliver clear decision support. Fourth, invest in patient education and support services to improve adherence with immunotherapy regimens and to ensure safe, appropriate use of at-home testing. Finally, pursue selective partnerships that accelerate market entry and expand geographic footprint without diluting core technical competencies. Taken together, these steps help organizations manage risk, accelerate uptake, and demonstrate measurable value to clinicians, payers and patients.

Transparent research methodology outlining data sources, analytical approaches, validation steps, and ethical considerations to produce robust industry insights

This research is grounded in a structured methodology that combines primary stakeholder engagement, rigorous secondary-source synthesis, and iterative validation. Primary inputs include interviews and consultations with clinicians, laboratory directors, commercial executives, payers, and patient advocacy representatives to ensure findings reflect real-world decision drivers. Secondary synthesis draws on peer-reviewed literature, regulatory guidance, clinical trial registries and publicly available technical information to contextualize primary insights.

Analytical approaches incorporate qualitative thematic analysis, comparative assessment across segmentation dimensions, and scenario-based evaluation of supply chain and policy impacts. Validation steps include cross-checking key conclusions with subject-matter experts and reconciling divergent perspectives through triangulation. Ethical considerations guide anonymization of interview data and the transparent representation of limitations. This combination of methods ensures the analysis is robust, actionable, and relevant to clinical, commercial and policy audiences.

Regional conclusion summarizing implications for stakeholders, emphasizing innovation pathways, operational resilience, collaborative models advancing patient outcomes

The body of evidence examined indicates that sustained progress in allergy diagnostics and therapeutics depends on coordinated efforts across technological development, evidence generation, supply chain resilience and stakeholder engagement. Diagnostic precision enables better patient stratification, while diversified therapeutic modalities offer opportunities to shift from symptom control to disease modification. At the same time, regulatory and reimbursement realities require targeted evidence and constructive payer engagement to achieve routine clinical adoption.

Looking ahead, organizations that integrate cross-functional planning-combining clinical validation, pragmatic deployment pathways, and patient-centered support-will be best placed to convert innovation into measurable outcomes. Collaboration across industry, clinical systems and policy stakeholders will remain essential for overcoming barriers related to access, affordability and operational complexity. In this context, clear strategic priorities and disciplined execution will determine which initiatives deliver the greatest clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Food Allergy Diagnostics & Therapeutics Market, by Product Type

  • 8.1. Diagnostic Tests
    • 8.1.1. At-Home Allergy Tests
    • 8.1.2. Component Resolved Diagnostics
    • 8.1.3. Skin Prick Tests
    • 8.1.4. Specific IgE Tests
  • 8.2. Therapeutic Products
    • 8.2.1. Antihistamines
    • 8.2.2. Emergency Treatments
    • 8.2.3. Immunotherapy
      • 8.2.3.1. Epicutaneous Immunotherapy
      • 8.2.3.2. Oral Immunotherapy
      • 8.2.3.3. Subcutaneous Immunotherapy
    • 8.2.4. Monoclonal Antibodies

9. Food Allergy Diagnostics & Therapeutics Market, by Allergen Type

  • 9.1. Egg Allergy
  • 9.2. Fish Allergy
  • 9.3. Milk Allergy
  • 9.4. Peanut Allergy
  • 9.5. Sesame Allergy
  • 9.6. Shellfish Allergy
  • 9.7. Soy Allergy
  • 9.8. Tree Nut Allergy
  • 9.9. Wheat Allergy

10. Food Allergy Diagnostics & Therapeutics Market, by End User

  • 10.1. Hospital Laboratories
  • 10.2. Point-Of-Care Settings
  • 10.3. Reference Laboratories
  • 10.4. Research Institutes

11. Food Allergy Diagnostics & Therapeutics Market, by Distribution Channel

  • 11.1. Clinics & Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Online
  • 11.4. Pharmacies

12. Food Allergy Diagnostics & Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Food Allergy Diagnostics & Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Food Allergy Diagnostics & Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Food Allergy Diagnostics & Therapeutics Market

16. China Food Allergy Diagnostics & Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ALK-Abello A/S
  • 17.6. Allergy Therapeutics plc
  • 17.7. bioMerieux SA
  • 17.8. DBV Technologies S.A.
  • 17.9. Eurofins Scientific SE
  • 17.10. HAL Allergy Group
  • 17.11. HOB Biotech Group Corp. Ltd.
  • 17.12. HYCOR Biomedical
  • 17.13. Immunomic Therapeutics Inc.
  • 17.14. Lincoln Diagnostics Inc.
  • 17.15. Medeca Pharma AB
  • 17.16. NEOGEN Corporation
  • 17.17. Nestle Health Science S.A.
  • 17.18. Omega Diagnostics Group PLC
  • 17.19. Pfizer Inc.
  • 17.20. Prota Therapeutics Pty Ltd
  • 17.21. Quest Diagnostics Incorporated
  • 17.22. R-Biopharm AG
  • 17.23. Sanofi S.A.
  • 17.24. Siemens Healthineers AG
  • 17.25. Stallergenes Greer International S.A.
  • 17.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)